Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Debt to Equity (2022)

Denali Therapeutics (DNLI) has disclosed Debt to Equity for 1 consecutive years, with $0.0 as the latest value for Q4 2022.

  • On a quarterly basis, Debt to Equity changed N/A to $0.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $0.0, a N/A change, with the full-year FY2022 number at $0.0, changed N/A from a year prior.
  • Debt to Equity was $0.0 for Q4 2022 at Denali Therapeutics, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.0 in Q4 2022 to a low of $0.0 in Q3 2022.